Salarius Pharmaceuticals confirms ongoing Nasdaq trading for its shares

Error on S&P CapIQ: Salarius Pharmaceuticals clarifies that an error on the S&P CapIQ platform incorrectly stated that the company was delisted from Nasdaq, while its stock continues to trade under the ticker "SLRX."

Merger and Funding: The company completed a merger with Decoy Therapeutics and raised $8 million in a public offering, resulting in a combined cash position of approximately $14 million.

Focus on Drug Development: Salarius is advancing Decoy's pipeline of peptide conjugate therapeutics, aiming to simplify drug development and manufacturing processes.

Upcoming Projects: Over the next year, Decoy plans to file an Investigational New Drug application for a pan-coronavirus antiviral and progress on other antiviral programs targeting flu, COVID-19, and GI cancers.